Related Experiment Video

Updated: Apr 12, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

EGFR and MEK Blockade in Triple Negative Breast Cancer Cells

Monica Rosaria Maiello1, Amelia D'Alessio1, Simona Bevilacqua1

  • 1Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy.

Journal of Cellular Biochemistry
|May 12, 2015
PubMed

Insights

Combining MEK inhibitor selumetinib with EGFR inhibitor gefitinib shows synergistic effects against triple-negative breast cancer (TNBC). This combination overcomes resistance by targeting both ERK1/2 and AKT pathways, offering a potential new strategy for TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The RAF/MEK/ERK pathway is crucial in triple-negative breast cancer (TNBC).
  • Resistance to MEK inhibitors is a significant challenge in TNBC treatment.
  • Receptor tyrosine kinase-dependent PI3K/AKT pathway activation is a proposed mechanism for this resistance.

Purpose of the Study:

  • To investigate the combined effects of MEK1/2 inhibitor selumetinib and epidermal growth factor receptor (EGFR) inhibitor gefitinib in TNBC cell lines.
  • To analyze the impact of this combination on cell growth, signaling pathways (ERK1/2, AKT), and cell cycle progression.
  • To determine if EGFR blockade can enhance selumetinib's antitumor activity in TNBC.

Main Methods:

  • Utilized a panel of TNBC cell lines with varying sensitivity to selumetinib.
  • Treated cells with selumetinib alone and in combination with gefitinib.
  • Assessed cell growth inhibition (IC50), EGFR and ERK1/2 phosphorylation, AKT phosphorylation, cell cycle distribution, and apoptosis.

Main Results:

  • Selumetinib treatment increased EGFR phosphorylation in both sensitive and resistant TNBC cells.
  • The combination of selumetinib and gefitinib demonstrated synergistic growth inhibition across all tested TNBC cell lines.
  • Combined treatment led to near-complete suppression of ERK1/2 activation and reduced AKT phosphorylation.
  • In selumetinib-sensitive cells, the combination induced significant G0/G1 cell cycle arrest and apoptosis.

Conclusions:

  • EGFR blockade can enhance the antitumor activity of selumetinib in a subset of TNBC.
  • The synergistic effect is associated with the combined inhibition of ERK1/2 and AKT signaling pathways.
  • This combination therapy presents a promising strategy for overcoming MEK inhibitor resistance in TNBC.
Keywords:
GEFITINIBSELUMETINIBTRIPLE NEGATIVE BREAST CANCER

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.4K